Technology | October 21, 2011

FDA Clears Segasist Prostate Auto-Contouring Treatment Planning Software

October 21, 2011 — Segasist Technologies, a Canadian software company, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its prostate auto-contouring software Segasist P-AC. 

The software is a tool developed for the purpose of segmenting magnetic resonance (MR), computed tomography (CT) and ultrasound images of the prostate gland for diagnostic and treatment-planning purposes. It can be trained by individual clinicians to accurately and quickly process prostate images, including fast slice-by-slice auto-contouring and volumetric calculations.

It was externally validated at the London Health Sciences Centre (London, Ontario). Experts from the Sunnybrook Research Institute and Sunnybrook Health Sciences Centre (Toronto, Ontario) also participated in the validation process by providing input in the form of gold standard contours.

The current version of Segasist P-AC is a complete segmentation solution able to adjust the contouring process for prostate delineation in any modality. It can improve the segmentation result by adjusting its contouring techniques using images previously marked by the clinician. That gives the clinical expert the opportunity to use his own markings to train the software, even though the software can also be delivered pre-trained.

For more information: www.segasist.com

Related Content

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
RaySearch Releases New Version of RayCare OIS
Technology | Oncology Information Management Systems (OIMS) | July 13, 2018
RaySearch has released RayCare 2A, the latest version of its flagship oncology information system (OIS). RayCare is...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Feature | Treatment Planning | July 03, 2018 | By Jeff Zagoudis
A new software developed and recently tested at the MD Anderson Cancer Center demonstrated the ability to largely aut
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Overlay Init